1
Clinical Trials associated with GSK-3206640AAn Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals' H7N9 influenza vaccine in subjects 18 to 64 years of age.
100 Clinical Results associated with GSK-3206640A
100 Translational Medicine associated with GSK-3206640A
100 Patents (Medical) associated with GSK-3206640A
100 Deals associated with GSK-3206640A